2026-05-10 · 2026-05 / week-1

Assertio Trades Above Cash Despite Tender Delays

Assertio Trades Above Cash Despite Tender Delays

Summary: Assertio Holdings (Nasdaq: ASRT) closed at $22.50 on Friday, May 8, 2026, and still traded $22.21 after hours, even though Garda Capital's amended merger price is only $21.80 in cash. That is not a normal merger spread. It is the market paying above a signed cash price after the parties delayed the tender launch a second time, to Wednesday, May 14, 2026, and before shareholders have even seen the live Schedule TO and 14D-9 materials. The variant view is simple: the premium above cash is too generous unless a real topping bid exists or Garda is about to pay more again, and neither fact is public today.

Opportunity Ranking

Rank Idea Discovery Lane Why It May Be Best Now Evidence Freshness Catalyst Window Asymmetry Main Reason to Reject
1 Short ASRT above the unchanged $21.80 cash bid U.S. special situation / above-bid merger spread ASRT closed at $22.50 on May 8, 2026 and traded $22.21 after hours even though Garda's signed amended price is only $21.80 cash, the tender still has not launched, and the parties just pushed commencement to May 14. StockAnalysis price page crawled May 10, 2026; Garda delay press release dated May 8, 2026; SEC 8-K and amended merger press release dated May 4, 2026; Q1 2026 10-Q due by May 11, 2026. May 11 Q1 2026 10-Q, May 14 tender launch target, July 2 outside date. Base-case downside to cash is modest, but a failed or re-cut deal can send the stock back toward the mid-teens. A live superior bidder may still exist, or Garda may bump the price again.
2 Residual Augmentum Fintech scheme spread into May 13 effectiveness Non-U.S. U.K. cash scheme Augmentum's board-backed 111p all-cash scheme has a May 11 court sanction hearing and expected May 13 effective date, but the shares were already quoted around 111.00p on May 8. Fidelity U.K. quote page and scheme timetable pages surfaced in May 10, 2026 search results. May 11 court sanction and May 13 expected effective date. Real event path, but almost no spread remains. Good process, weak payoff.
3 Long ETH versus BTC after the weekend reset Liquid crypto major / ratio trade Bitcoin was quoted around $80,951 and ether around $2,329 on May 10, 2026, which leaves ETH/BTC near 0.0288. OpenAI finance snapshot, May 10, 2026. Crypto trades continuously; no single hard near-term catalyst was strong enough in current search. Deep liquidity and easy implementation. The rebound has already happened enough that the surprise content is weaker than ASRT.

Selected opportunity: Short ASRT above the unchanged $21.80 cash bid.

Why this one now: The tape is paying above a signed cash price even though the most recent hard information is process friction, not improvement. The tender still has not commenced, the deal now depends on a May 11 balance-sheet update and a May 14 filing target, and the stock is still printing above cash.

What should surprise the reader: A sophisticated reader should not be surprised that ASRT has a bid. The surprise is that the stock is still above the bid after two launch delays and before the live offer documents exist.

The Setup

Assertio is no longer a normal diversified specialty-pharma story. On April 8, 2026, the company closed the sale of its non-ROLVEDON assets to Cosette and effectively turned itself into a much simpler oncology vehicle. That same day, Garda agreed to buy Assertio for $18.00 per share in cash plus one non-tradeable CVR.

That first deal did not last. On May 4, 2026, after the company received what the amended press release called a Superior Proposal, Garda and Assertio rewrote the merger. The CVR disappeared. The price moved to $21.80 in cash. Garda also disclosed financing commitments of $22.2 million of equity and $130.0 million of debt. The board again recommended that holders tender.

The problem is the clock. Under the amended merger agreement, the tender was supposed to launch by May 4. Instead, the parties first postponed commencement to May 8, then postponed it again to May 14. Assertio said it expects to file its Form 10-Q for the quarter ended March 31, 2026 by Monday, May 11, and only then file the Schedule TO and 14D-9 on Wednesday, May 14.

That is the whole point of the trade. The price is above cash while the documentation is moving the wrong way.

The Mispricing

The market is telling one of two stories.

The first story is bullish optionality. A real superior bidder may still be in the room, even if undisclosed, and the stock deserves to trade above Garda's cash because another bump is possible.

The second story is mechanical optimism. Traders may believe the launch delay is paperwork, the Q1 10-Q will easily satisfy the merger's balance-sheet condition, and the stock deserves to sit slightly above cash because closing quality has improved.

The variant view is harsher. The public evidence does not show a live topping bid. It shows the opposite: repeated delay, still-missing tender documents, and a merger condition that now matters more than the market seems willing to admit. The amended merger requires Assertio to deliver at least $95 million of closing net cash. Yet the latest fully reported balance-sheet disclosure, in the fourth-quarter and full-year 2025 results, showed only $63.4 million of cash, cash equivalents, and short-term investments at December 31, 2025. The April asset sale likely improved that number, but the public still has to see the Q1 filing.

In plain English, the stock is trading above cash before the market has the document that tells it whether the balance-sheet condition is comfortably satisfied.

Price

Market Level Current Reading Source / Timestamp Why It Matters
ASRT close $22.50 StockAnalysis price page, latest regular-session close on May 8, 2026, 4:00 PM EDT Clean anchor for current premium to cash.
ASRT after hours $22.21 StockAnalysis price page, May 8, 2026, 7:18 PM EDT Shows the stock remained above bid after the close.
Garda amended merger price $21.80 cash per share Assertio / Garda amended merger press release filed with the SEC on May 4, 2026 The signed headline cash price.
Premium above cash bid 3.2% at the close, 1.9% after hours Calculated from $22.50 and $22.21 versus $21.80 Measures the premium the market is paying for optionality.
Implied unaffected price About $13.37 Calculated from the disclosed 63.1% premium in the May 4, 2026 press release Frames the break-risk downside if the bid collapses.
12-month analyst target $19.90 StockAnalysis analyst-consensus page, crawled May 10, 2026 Sell-side consensus sits below the tape, not above it.
Minimum closing net cash $95.0 million May 4, 2026 8-K summary of amended merger terms Load-bearing deal condition.
Latest fully reported cash, cash equivalents, and short-term investments $63.4 million at December 31, 2025 Assertio fourth-quarter and full-year 2025 results, filed March 16, 2026 Explains why the May 11 10-Q matters so much.
Outside date July 2, 2026 May 4, 2026 8-K summary Tells you how long the process can run before either side can walk.

The price disagreement is not subtle. A clean cash deal trades below cash, not above it. Above-bid prices exist when the market believes the signed number is stale.

Positioning

Direct live borrow and short-interest evidence were not safely available in the current run, and that absence matters. This thesis should not pretend to know the borrow tape.

What is visible is the positioning inside the price. Someone is still willing to own ASRT above a signed cash value even after two commencement delays. That is either merger-arb capital paying for topping-bid optionality or a thinner, more reflexive event crowd assuming the Q1 10-Q will erase the balance-sheet concern.

The counterweight is the sell-side anchor. The 12-month analyst target shown on the current StockAnalysis page is $19.90, below both the live stock price and the cash bid. Analysts are not publicly underwriting a higher number.

Volume also matters. The same page showed only 81,858 shares in the latest session. This is enough liquidity for a note, not enough liquidity to assume the premium is a robust institutional consensus.

Catalyst

The first catalyst is Monday, May 11, 2026, when Assertio expects to file its Q1 2026 Form 10-Q. That filing should materially improve or weaken confidence in the $95 million closing-net-cash condition.

The second catalyst is Wednesday, May 14, 2026, when the parties now expect to launch the tender and file the Schedule TO and 14D-9. If those documents appear with no price increase and no new bidder, the above-cash premium should be harder to defend.

The third catalyst is the absence of a catalyst. If May 14 slips again, the market has to decide whether it is still trading a real merger or merely trading hope around a prior superior-proposal leak.

The last date that matters is July 2, 2026. That is the outside date embedded in the amended merger. It is not tomorrow, but it stops this from turning into an endless rumor trade.

The Gap

The market is not missing the deal. It is overpaying for one of two things: a hidden bidder or a cleaner process than the filings currently support.

That premium may look small because the cash bid is only $0.70 below the close. That is the wrong way to think about it. On the downside, unchanged terms only get the stock back to cash. On the upside for the short, a real failure or material re-trade can send the equity back toward the pre-bump zone, because the May 4 press release itself framed $21.80 as a 63.1% premium to the unaffected March 20 price.

This is why the trade works as a special-situations note rather than as lazy merger math. The base case is not huge. The tail is.

Payoff Map

The cleanest expression is short ASRT common stock only with confirmed borrow and tolerable carry. The stock is above cash. If nothing improves, the premium should compress. If the merger actually breaks, the move is much larger.

The second-best expression is an options-first short if a live put chain can be verified at acceptable spreads. That would define the risk better if a superior bidder emerges. No live option-chain data were safely available in the current run, so the main article does not pretend otherwise.

The wrong expression is a casual long. Being long above a signed cash price means paying for optionality the public record does not yet prove.

Price Target and Probability Map

Scenario Probability Target / Level Return / Payoff Time Horizon Conditions Required Evidence Quality
Top Case 20% $14.50 About +35.6% on a short from $22.50 Two to eight weeks Q1 10-Q or tender documents expose real balance-sheet strain, the above-bid premium collapses, and no rival bidder appears. Medium
Base Case 55% $21.80 About +3.1% on a short from $22.50 One to three weeks Tender launches on May 14 at unchanged terms and the stock converges to signed cash. High
Bottom Case 25% $24.50 About -8.9% on a short from $22.50 One to eight weeks A rival bidder reappears, Garda bumps again, or the May 11 and May 14 disclosures prove much cleaner than the market feared. Low
Invalidation / Stop Condition n/a Sustained trade above $24.75 or a signed higher bid Thesis break, not a price target Immediate through process window The market receives a real price-improvement event rather than mere optionality. High

Probability-weighted expected value: Using the price map above, the expected stock level is about $21.02. From a $22.50 short entry anchor, that implies roughly +6.6% probability-weighted expected return before borrow cost, commissions, taxes, and gap risk.

Current market price / level: ASRT closed at $22.50 on May 8, 2026 at 4:00 PM EDT and traded $22.21 after hours at 7:18 PM EDT, still above the $21.80 cash bid.

Timestamp: Research completed May 10, 2026, 20:49 Asia/Ho_Chi_Minh (UTC+07:00).

Primary instrument: ASRT common stock on Nasdaq.

Alternative expressions considered: Puts or a bear put spread if the live chain is liquid enough, or no trade until May 11 and May 14 remove the key unknowns.

Confidence: Medium-low.

What Could Go Wrong

The obvious loss path is a real topping bid. The May 4 amended press release already admitted that a superior proposal once existed. If that bidder is still active, the stock deserves to sit above Garda's cash and can sit higher still.

The subtler loss path is process clarity. If the Q1 10-Q shows a very comfortable cash position, the May 14 tender launches cleanly, and no new friction appears, the premium can persist longer than a short wants.

There is also a structural risk the article cannot solve for you: borrow. An event-driven short in a small-cap pharma name can become expensive or unavailable at exactly the wrong time.

What Would Prove This Wrong

The thesis fails if a bona fide higher bidder signs or if Garda itself revises the price upward again. It also fails if ASRT trades sustainably above $24.75 on concrete deal improvement rather than on rumor.

A clean May 11 10-Q does not by itself invalidate the thesis. A clean May 14 launch does not by itself invalidate it either. Those events mostly collapse the premium back toward $21.80. What invalidates the idea is actual price improvement.

Risk Audit

Strongest counterargument: The market may not be irrational at all. It may simply be pricing the possibility that the previously disclosed superior proposal is real and still alive. In that world, the above-cash premium is not a mistake. It is the right probability-weighted clearing price.

Most fragile assumption: That the public record is closer to the full truth than the tape is. If informed event funds know more about rival-bid persistence than the filings show, the short is wrong.

What the market may already know: The company already sold non-ROLVEDON assets on April 8, 2026. That may have repaired the cash position enough that the $95 million closing-net-cash condition is routine rather than risky.

What could make the trade lose money even if the thesis is directionally right: Even without a higher bid, the stock can hover above $21.80 for days or weeks because the free float is thin and event-driven holders may refuse to sell into a pending launch.

Liquidity / execution risks: Thin volume, uncertain borrow, and potential gap moves on SEC filings make this inappropriate for large size.

Leverage risks: Leverage is a bad fit. The upside to unchanged cash is small, while the loss from a higher bid is discontinuous.

Information reliability risks: The key open variable is the not-yet-filed Q1 10-Q. The article can only underwrite what is public today.

Invalidation trigger: Signed superior proposal, revised Garda price, or sustained trade above $24.75 on real deal improvement.

Publish / revise / reject recommendation: Publish as a medium-low confidence short event note. The setup is real, but it depends on respecting missing information rather than hand-waving it away.

Bottom Line

ASRT is trading above cash while the deal clock is slipping. That is the disagreement. The market is paying for optionality that may exist, but the filings do not yet prove it. The best expression is short ASRT, sized small, only with confirmed borrow or a verified put structure. If the May 11 and May 14 disclosures do not improve the price, the premium to cash should compress. If a real higher bidder shows up, step aside and admit the tape was smarter.

Sources

Best Trade Strategy

The trade is short ASRT, preferably through a verified put structure if the live chain is liquid enough, and otherwise through borrowed common stock only after confirmable locate and carry checks. It is not a long.